|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-3-4
|
|
pubmed:abstractText |
Targeting malignant B cells using rituximab (anti-CD20) has improved the efficacy of chemotherapy regimens used to treat patients with non-Hodgkin's lymphoma. Despite the promising clinical results obtained using rituximab, many patients relapse with therapy-resistant disease following rituximab-based treatments. We have created a cell line model of rituximab resistance using three B-cell non-Hodgkin's lymphoma-derived cell lines (Raji, RL, and SUDHL-4). In an attempt to define strategies to overcome rituximab resistance, we sought to determine the chemotherapy sensitivity of our rituximab-resistant cell lines (RRCL).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/BAK1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/BAX protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Caspases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/bcl-2 Homologous Antagonist-Killer...,
http://linkedlifedata.com/resource/pubmed/chemical/bcl-2-Associated X Protein,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1550-60
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18316580-Antibodies, Monoclonal,
pubmed-meshheading:18316580-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18316580-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:18316580-Antineoplastic Agents,
pubmed-meshheading:18316580-Apoptosis,
pubmed-meshheading:18316580-Blotting, Western,
pubmed-meshheading:18316580-Caspases,
pubmed-meshheading:18316580-Drug Resistance, Neoplasm,
pubmed-meshheading:18316580-Humans,
pubmed-meshheading:18316580-Lymphoma, B-Cell,
pubmed-meshheading:18316580-Membrane Potential, Mitochondrial,
pubmed-meshheading:18316580-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:18316580-RNA, Messenger,
pubmed-meshheading:18316580-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18316580-Tumor Cells, Cultured,
pubmed-meshheading:18316580-bcl-2 Homologous Antagonist-Killer Protein,
pubmed-meshheading:18316580-bcl-2-Associated X Protein
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
|
|
pubmed:affiliation |
Departments of Immunology and Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
